Radiotherapy-induced hypopituitarism: A review

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 669-683

  Sathyapalan, Thozhukat ^a   Dixit, Sanjay ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

cancer survivors; hypopituitarism; late effect; nasopharyngeal cancer; neuroendocrinopathy; pituitary; pituitary dysfunction; radiotherapy; skull base tumors; toxicity

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CABERGOLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOKINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADORELIN DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYDROCORTISONE; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON; IPILIMUMAB; LEVOTHYROXINE; LUTEINIZING HORMONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PROGESTERONE; PROTEIN TYROSINE KINASE INHIBITOR; PROTIRELIN; TESTOSTERONE; THYROTROPIN; UNINDEXED DRUG; YTTRIUM 90;

AGE; ANTINEOPLASTIC ACTIVITY; BRACHYTHERAPY; BRAIN TUMOR; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CORTICOTROPIN DEFICIENCY; DRUG DOSE INCREASE; DRUG INSTILLATION; DRUG MEGADOSE; EARLY MENOPAUSE; ENDOCRINE DISEASE; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL SYMPTOM; GONADOTROPIN DEFICIENCY; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INTRACRANIAL TUMOR; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; NASOPHARYNX TUMOR; NONHUMAN; PARANASAL SINUS TUMOR; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION INDUCED HYPOPITUITARISM; RADIATION INJURY; RADIATION PROTECTION; REVIEW; RISK FACTOR; SARCOMA; SEX DIFFERENCE; SKULL BASE TUMOR; SKULL IRRADIATION; STEREOTACTIC BODY RADIATION THERAPY; SUBCLINICAL GLUCOCORTICOID DEFICIENCY; THYROTROPIN DEFICIENCY; VALVULAR HEART DISEASE; WHOLE BODY RADIATION;

ADULT; CHILD; EARLY DIAGNOSIS; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPITUITARISM; PITUITARY FUNCTION TESTS; PITUITARY GLAND; RADIOSURGERY; RADIOTHERAPY; RISK FACTORS; STEREOTAXIC TECHNIQUES;

EID: 84861308420     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.27     Document Type: Review

References (107)

1. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355(15), 1572-1582 (2006).
2. Oeffinger KC, Tonorezos ES. The cancer is over, now what?: Understanding risk, changing outcomes. Cancer 117(Suppl. 10), 2250-2257 (2011).
3. Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr. Relat. Cancer 17(3), R141-R159 (2010).
4. Benesch M, Lackner H, Sovinz P et al. Late sequela after treatment of childhood low-grade gliomas: A retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J. Neurooncol. 78(2), 199-205 (2006).
5. Mulder RL, Kremer LCM, Santen HMV et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat. Rev. 35(7), 616-632 (2009).
6. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96(8), 2330-2340 (2011).
7. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. Endocr. Relat. Cancer 16(3), 733-772 (2009).
8. Wachter D, Gondermann N, Oertel MF, Nestler U, Rohde V, Boker DK. Pituitary insufficiency after operation of supratentorial intra- and extra-axial tumors outside of the sellar-parasellar region? Neurosurg. Rev. 34(4), 509-516 (2011).
9. Arafah BM. Medical management of hypopituitarism in patients with pituitary adenomas. Pituitary 5, 109-117 (2002).
10. Schoenfeld GO, Amdur RJ, Schmalfuss IM et al. Low-dose prophylactic craniospinal radiotherapy for intracranial germinoma. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 481-485 (2006).
11. De Marinis L, Fusco A, Bianchi A et al. Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J. Endocrinol. Invest. 29(6), 516-522 (2006).
12. Gonzalez B, Vargas G, Espinosa-De-Los- Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in acromegaly. Arch. Med. Res. 42(1), 48-52 (2011).
13. Merchant TE, Williams T, Smith JM et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int. J. Radiat. Oncol. Biol. Phys. 54(1), 45-50 (2002).
14. Schmiegelow M. Endocrinological late effects following radiotherapy and chemotherapy of childhood brain tumours. Dan. Med. Bull. 53, 326-341 (2006).
15. Borson-Chazot F, Brue T. Pituitary deficiency after brain radiation therapy. Ann. Endocrinol. (Paris) 67(4), 303-309 (2006).
16. Di Mambro A, Giuliani C, Ammannati F et al. A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters. J. Endocrinol. Invest. 33(7), 455-460 (2010).
17. Dropcho EJ. Central nervous system injury by therapeutic irradiation. Neurol. Clin. 9(4), 969-988 (1991).
18. Clark AJ, Chahal P, Mashiter K, Joplin GF. Lack of rise in serum prolactin following yttrium-90 interstitial irradiation for acromegaly. Clin. Endocrinol. (Oxf.) 19(5), 557-563 (1983).
19. Chieng PU, Huang TS, Chang CC, Chong PN, Tien RD, Su CT. Reduced hypothalamic blood flow after radiation treatment of nasopharyngeal cancer: SPECT studies in 34 patients. AJNR Am. J. Neuroradiol. 12(4), 661-665 (1991).
20. Roth C, Lakomek M, Schmidberger H, Jarry H. Cranial irradiation induces premature activation of the gonadotropin-releasing-hormone. Klin. Padiatr. 213(4), 239-243 (2001).
21. Nishioka H, Hirano A, Haraoka J, Nakajima N. Histological changes in the pituitary gland and adenomas following radiotherapy. Neuropathology 22(1), 19-25 (2002).
22. Feigl GC, Pistracher K, Berghold A, Mokry M. Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. J. Neurosurg. 113(Special Suppl.), 153-159 (2010).
23. Degerblad M, Brismar K, Rahn T, Thoren M. The hypothalamus-pituitary function after pituitary stereotactic radiosurgery: evaluation of growth hormone deficiency. J. Intern. Med. 253(4), 454-462 (2003).
24. Fajardo LF. Ionizing radiation and the endothelium. In:CURED I-LENT Late Effects of Cancer Treatment on Normal Tissues. Rubin P CLS, Marks LB, Okunieff P (Eds). Springer, Berlin, Germany, 19-22 (2008).
25. Schaeffer M, Hodson DJ, Lafont C, Mollard P. Endocrine cells and blood vessels work in tandem to generate hormone pulses. J. Mol. Endocrinol. 47(2), R59-R66 (2011).
26. Darzy KH, Pezzoli SS, Thorner MO, Shalet SM. Cranial irradiation and growth hormone neurosecretory dysfunction: a critical appraisal. J. Clin. Endocrinol. Metab. 92(5), 1666-1672 (2007).
27. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J. Clin. Endocrinol. Metab. 88(1), 95-102 (2003).
28. Paulino AC, Jhaveri P, Dreyer Z, Teh BS, Okcu MF. Height impairment after lower dose cranial irradiation in children with acute lymphoblastic leukemia. Pediatric Blood Cancer 56(2), 279-281 (2011).
29. Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. J. Pediatr. 118(2), 226-228 (1991).
30. Constine LS, Woolf PD, Cann D et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N. Engl. J. Med. 328(2), 87-94 (1993).
31. Lam KS, Tse VK, Wang C, Yeung RT, Ho JH. Effects of cranial irradiation on hypothalamic-pituitary function - a 5-year longitudinal study in patients with nasopharyngeal carcinoma. Q. J. Med. 78(286), 165-176 (1991).
32. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q. J. Med. 70(262), 145-160 (1989).
33. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J. Clin. Oncol. 27(22), 3691-3697 (2009).
34. Cheuk DK, Billups CA, Martin MG et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 117(1), 197-206 (2011).
35. Agha A, Sherlock M, Brennan S et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J. Clin. Endocrinol. Metab. 90(12), 6355-6360 (2005).
36. Snyers A, Janssens GO, Twickler MB et al. Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1343-1351 (2009).
37. Sara M, Claudio F, Marco L et al. Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother. Oncol. 99(1), 23-28 (2011).
38. Littley MD, Shalet SM, Beardwell CG, Robinson EL, Sutton ML. Radiation-induced hypopituitarism is dose-dependent. Clin. Endocrinol. (Oxf.) 31(3), 363-373 (1989).
39. Linsenmeier C, Thoennessen D, Negretti L et al. Total body irradiation (TBI) in pediatric patients. Strahlenther. Onkol. 186(11), 614-620 (2010).
40. Castinetti F, Nagai M, Morange I et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J. Clin. Endocrinol. Metab. 94(9), 3400-3407 (2009).
41. Pai HH, Thornton A, Katznelson L et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose- effect relationship using dose-volume histogram analysis. Int. J. Radiat. Oncol. Biol. Phys. 49(4), 1079-1092 (2001).
42. Marek J, Jezkova J, Hana V et al. Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell Gamma Knife? Eur. J. Endocrinol. 164(2), 169-178 (2011).
43. Castinetti F, Regis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat. Rev. Endocrinol. 6(4), 214-223 (2010).
44. Feigl GC, Pistracher K, Berghold A, Mokry M. Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. J. Neurosurg. 113(Suppl.) 153-159 (2010).
45. Pollock BE, Cochran J, Natt N et al. Gamma Knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int. J. Radiat. Oncol. Biol. Phys. 70(5), 1325-1329 (2008).
46. Felicetti F, Manicone R, Corrias A et al. Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J. Cancer Res. Clin. Oncol. 137(9), 1343-1348 (2011).
47. Bakker B, Oostdijk W, Geskus RB, Stokvis-Brantsma WH, Vossen JM, Wit JM. Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood. Clin. Endocrinol. (Oxf.) 67(4), 589-597 (2007).
48. Ogilvy-Stuart AL, Shalet SM. Effect of chemotherapy on growth. Acta Paediatr. Suppl. 411, 52-56 (1995).
49. Olshan JS, Gubernick J, Packer RJ et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 70(7), 2013-2017 (1992).
50. Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 33(10), 1049-1056 (2004).
51. Rose SR, Schreiber RE, Kearney NS et al. Hypothalamic dysfunction after chemotherapy. J. Pediatr. Endocrinol. Metab. 17(1), 55-66 (2004).
52. Haddy TB, Mosher RB, Nunez SB, Reaman GH. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatric Blood Cancer 46(2), 258-261 (2006).
53. Constine LS, Rubin P, Woolf PD, Doane K, Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J. Clin. Oncol. 5(11), 1841-1851 (1987).
54. Van Santen HM. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J. Clin. Endocrinol. Metabol. 88(8), 3657-3663 (2003).
55. Bilgir O, Kebapcilar L, Bilgir F et al. Is there any relationship between imatinib mesylate medication and hypothalamic- pituitary-adrenal axis dysfunction? Int. J. Clin. Pract. 64(1), 45-50 (2010).
56. Kebapcilar L, Bilgir O, Alacacioglu I et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med. Princ. Pract. 18(5), 360-363 (2009).
57. Sukumari-Ramesh S, Singh N, Dhandapani KM, Vender JR. mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surg. Neurol. Int. 2, 22 (2011).
58. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune-related adverse events across a spectrum of cancer subtypes. Pituitary 13(1), 29-38 (2010).
59. Beltran SRM, Berlier P, Sunyach MP, Borson-Chazot F, Frappaz D. Endocrine function after craniospinal irradiation for medulloblastoma in children and adults. Neuro. Oncol. 11(5), 659 (2009).
60. Shalitin S, Gal M, Goshen Y, Cohen I, Yaniv I, Phillip M. Endocrine outcome in long-term survivors of childhood brain tumors. Hormone Res. Paediatrics 76(2), 113-122 (2011).
61. Lam KS, Ho JH, Lee AW et al. Symptomatic hypothalamic-pituitary dysfunction in nasopharyngeal carcinoma patients following radiation therapy: a retrospective study. Int. J. Radiat. Oncol. Biol. Phys. 13(9), 1343-1350 (1987).
62. Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Hypopituitarism after radiotherapy for extracranial head and neck cancers. Head Neck 30(9), 1182-1192 (2008).
63. Ayuk J, Stewart PM. Mortality following pituitary radiotherapy. Pituitary 12(1), 35-39 (2009).
64. Bercu BB, Diamond FB Jr. Growth hormone neurosecretory dysfunction. Clin. Endocrinol. Metab. 15(3), 537-590 (1986).
65. Laughton SJ, Merchant TE, Sklar CA et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J. Clin. Oncol. 26(7), 1112-1118 (2008).
66. Diller L, Chow EJ, Gurney JG et al. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. J. Clin. Oncol. 27(14), 2339-2355 (2009).
67. Jarfelt M, Bjarnason R, Lannering B. Young adult survivors of childhood acute lymphoblastic leukemia: spontaneous GH secretion in relation to CNS radiation. Pediatric Blood Cancer 42(7), 582-588 (2004).
68. Verhelst J, Mattsson AF, Luger A et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur. J. Endocrinol. 165(6), 881-889 (2011).
69. Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Horm IGF Res. 16(Suppl. A), S30-S40 (2006).
70. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur. J. Endocrinol. 152(2), 165-170 (2005).
71. Murray RD, Adams JE, Smethurst LE, Shalet SM. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency. Clin. Endocrinol. (Oxf.) 56(2), 169-174 (2002).
72. Armstrong GT, Liu Q, Yasui Y et al. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J. Clin. Oncol. 27(14), 2328-2338 (2009).
73. Ergun-Longmire B, Mertens AC, Mitby P et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab. 91(9), 3494-3498 (2006).
74. Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Hormone Res. 46(3), 113-116 (1996).
75. Clemmons DR. The diagnosis and treatment of growth hormone deficiency in adults. Curr. Opin. Endocrinol. Diabetes Obes. 17(4), 377-383 (2010).
76. Green DM, Kawashima T, Stovall M et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 27(16), 2677-2685 (2009).
77. Bath LE, Anderson RA, Critchley HO, Kelnar CJ, Wallace WH. Hypothalamic- pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Human Reproduct. (Oxf. Engl.) 16(9), 1838-1844 (2001).
78. Gross KM, Matsumoto AM, Southworth MB, Bremner WJ. Evidence for decreased luteinizing hormone-releasing hormone pulse frequency in men with selective elevations of follicle-stimulating hormone. J. Clin. Endocrinol. Metab. 60(1), 197-202 (1985).
79. Wildt L, Hausler A, Marshall G et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology 109(2), 376-385 (1981).
80. Laporte S, Couto-Silva AC, Trabado S et al. Inhibin B and anti-Müllerian hormone as markers of gonadal function after hematopoietic cell transplantation during childhood. BMC Pediatr. 11, 20 (2011).
81. Livesey EA, Hindmarsh PC, Brook CG et al. Endocrine disorders following treatment of childhood brain tumours. Br. J. Cancer 61(4), 622-625 (1990).
82. Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q. J. Med. 78(287), 265-274 (1991).
83. Ogilvy-Stuart AL, Clark DJ, Wallace WH et al. Endocrine deficit after fractionated total body irradiation. Arch. Dis. Childhood 67(9), 1107-1110 (1992).
84. Schneider HJ, Rovere S, Corneli G et al. Endocrine dysfunction in patients operated on for nonpituitary intracranial tumors. Eur. J. Endocrinol. 155(4), 559-566 (2006).
85. Pai HH, Thornton A, Katznelson L et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int. J. Radiat. Oncol. Biol. Phys. 49(4), 1079-1092 (2001).
86. Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 68(4), 1131-1139 (2007).
87. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat. Clin. Pract. Endocrinol. Metab. 5(2), 88-99 (2009).
88. Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-screening tumors and hypogonadism in 22 men. N. Engl. J. Med. 299(16), 847-852 (1978).
89. Sham J, Choy D, Kwong PW et al. Radiotherapy for nasopharyngeal carcinoma: shielding the pituitary may improve therapeutic ratio. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 699-704 (1994).
90. Coons JM, Moreman C, Ragains M, Scalf K, Vitaz T, Spalding A. Improvement of therapeutic index for brain tumors with daily image guidance. Int. J. Radiat. Oncol. Biol. Phys. 78(3), S277-S278 (2010).
91. Alapetite C, Puget S, Bolle S et al. Protontherapy for craniopharyngioma in children: the Orsay proton center experience. Pediat. Blood Cancer 55(5), 791-792 (2010).
92. Minniti G, Clarke E, Cavallo L et al. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiation Oncol. 6, 36 (2011).
93. Shih HA, Arvold ND, Niemierko A, Broussard GP, Fullerton B, Loeffler JS. Second tumor risk and projected late effects after proton vs intensity modulated photon radiotherapy for benign meningioma: a dosimetric comparison. Int. J. Radiat. Oncol. Biol. Phys. 78(3), S272 (2010).
94. Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev. Endocr. Metab. Disord. 10(2), 135-144 (2009).
95. Udalova N, Strebkova N, Kuznetsova E, Peterkova V. Long-term anterior pituitary function in a cohort of pediatric Cushing's disease after proton therapy. Hormone Res. Paediatr. 76(Suppl. 2), 49-118 (2011).
96. Iwata H, Sato K, Tatewaki K et al. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro. Oncol. 13(8), 916-922 (2011).
97. Taussky P, Kalra R, Coppens J, Mohebali J, Jensen R, Couldwell WT. Endocrinological outcome after pituitary transposition (hypophysopexy) and adjuvant radiotherapy for tumors involving the cavernous sinus. J. Neurosurg. 115(1), 55-62 (2011).
98. Onal C, Kayaselcuk F, Topkan E, Yavuz M, Bacanli D, Yavuz A. Protective effects of melatonin and octreotide against radiation-induced intestinal injury. Digest. Dis. Sci. 56(2), 359-367 (2011).
99. Landolt AM, Haller D, Lomax N et al. Octreotide may act as a radioprotective agent in acromegaly. J. Clin. Endocrinol. Metab. 85(3), 1287-1289 (2000).
100. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306(3), 269-276 (2011).
101. Minniti G, Saran F, Traish D et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother. Oncol. 82(1), 90-95 (2007).
102. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH. Overview of late effects normal tissues (LENT) scoring system. Radiother. Oncol. 35(1), 9-10 (1995).
103. Pavy JJ, Denekamp J, Letschert J et al. Late effects toxicity scoring: the SOMA scale. Radiother. Oncol. 35(1), 11-15 (1995).
104. No authors listed. LENT SOMA tables. Radiother. Oncol. 35(1), 17-60 (1995).
105. Johannesen TB, Hole KH, Rasmussen K et al. Late radiation injury of the centralnervous system, recording of morbidity according to the SOMA/LENT scoring system. Int. J. Radiat. Oncol. Biol. Phys. 51(3), 251-252 (2001).
106. Nandagopal R, Laverdiere C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Hormone Res. 69(2), 65-74 (2008).
107. Langsenlehner T, Stiegler C, Quehenberger F et al. Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther. Onkol. 183(5), 241-247 (2007).